hVIVO: A Guidance Cut Built on a Record Order Book
H1 2026 was the trough — the whole thesis rests on whether the deferred work actually lands in 2027.
HVO.L · Earnings Call · 2026-09-15
The Trough and the Backlog
On the face of it, hVIVO's interim print is ugly. First-half revenue fell to GBP 16.3m from GBP 24m a year earlier, and the company swung from profit to a GBP 4.5m EBITDA loss, with full-year guidance trimmed to GBP 47m — below the consensus nearer GBP 50–51m. CFO Stephen Pinkerton walked through the bridge bluntly: “GBP 24 million versus GBP 16.3 million... the huge difference here is the decline in the HCT revenues year on year.” — Stephen Pinkerton, CFO · 2026-09-15 Two large human challenge trial contracts slipped out of the period, and CEO Yamin 'Mo' Khan was emphatic about what that means: “this is mainly due to deferment and not cancellations.” — Yamin 'Mo' Khan, CEO · 2026-09-15
That distinction is the entire bull case. The order book — the company's top-ranked theme this quarter — sits at GBP 65m on an underlying basis, rising to GBP 72m with the newly acquired Berlin unit. Management calls this the highest in the company's history, built on a 45% year-on-year rise in new proposals and a 26% increase in proposal value. The bugbear is that hVIVO started 2026 with a thin GBP 30m backlog, so a couple of delays have outsized swing. Investors are being asked to trust that contracted work does not drift again.
We believe strongly that the first half of 2026 is a trough, and we'll see almost doubling of the revenue from the first half to the second half.
A Niche No Longer
The more interesting arc is strategic. hVIVO is trying to stop being "just" a human challenge trial house. Its human challenge franchise still delivers data roughly 3.5x faster than natural-infection studies, and the company just signed its largest ever such contract plus two influenza trials. But Andrew Catchpole flagged a genuine mix shift: “instead of being split between vaccines and antivirals, we're seeing more of it going towards antivirals,” — Andrew Catchpole, Unknown, likely senior management or scientific leadership · 2026-09-15 a change he characterizes as cyclical but currently well-funded. The antiviral versus vaccine rotation is the kind of nuance that rarely shows up in a headline number.
Meanwhile, less than half of 2026 revenue will now come from challenge work. A standalone laboratory service line grew 110%, and the CRS Berlin acquisition — modest EUR 25k up front, an earn-out scaling with revenue — brings dermatology, women's health, and capacity above 200 beds. In Mannheim, the Obesity opportunity is being pursued off the back of a diabetes-focused key opinion leader. “Historically, we've been a pure human challenge trial player. Now that we have the diversified business, I think it does dilute the human challenge trial change impact,” — Yamin 'Mo' Khan, CEO · 2026-09-15 Mo said, directly answering a question about why a few delayed trials can still swing the whole group from profit to loss.
What the Tape Cannot Tell Us
Notably, no price action was provided for this name, so the market's verdict is unavailable here — a limitation worth flagging rather than papering over. The cross-section that does exist is instructive, though: "order book" and "order intake" show up across other reporting companies like GVR.IR and CNC.L, suggesting backlog visibility is a broader theme in this earnings season rather than something unique to hVIVO. What is unique is the challenge-trial model inside a Biotech funding environment that management says is loosening.
On cash, the story is survivable but tightening: GBP 14.3m at the start of the year to GBP 13m at the half, guided down to roughly GBP 8–9m by December as fieldwork-heavy H2 work inflates receivables. The swing factor is mix. “HCT has the highest margin. It is great margin in this business. It is not yet fully back in our numbers in terms of revenue terms,” — Stephen Pinkerton, CFO · 2026-09-15 Pinkerton warned, noting the flagship ILiAD project is outpatient and therefore lower-margin than a classic challenge study.
The honest read: this is a small-cap transition story where the reported numbers are bad and the leading indicator is good. The deferred contracts are the whole bet. If they land, 2027 shows meaningful growth; if they slip again, the record challenge study backlog becomes a credibility problem rather than a catalyst.